Tanya I. Coulter

Belfast, NIR, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Management of hereditary angioedema in the UK: a comparison with international guidelines.

Management of hereditary angioedema in the UK: a comparison with international guidelines.

Journal: Clinical and experimental immunology

Published: June 17, 2026

Quality of life of X-linked agammaglobulinemia patients in the United Kingdom.

Quality of life of X-linked agammaglobulinemia patients in the United Kingdom.

Journal: Journal of human immunity

Published: September 15, 2025

National Audit of Long-Term Real-World Outcomes of Berotralstat Use in UK Patients With Hereditary Angioedema.

National Audit of Long-Term Real-World Outcomes of Berotralstat Use in UK Patients With Hereditary Angioedema.

Journal: Allergy

Published: July 17, 2025

Clinical and Molecular Characteristics of X-Linked Agammaglobulinemia Patients 55 Years or Older.

Clinical and Molecular Characteristics of X-Linked Agammaglobulinemia Patients 55 Years or Older.

Journal: The journal of allergy and clinical immunology. In practice

Published: April 01, 2025

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis.

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis.

Journal: Clinical immunology (Orlando, Fla.)

Published: August 23, 2024

Outcomes of X-Linked Agammaglobulinaemia Patients.

Outcomes of X-Linked Agammaglobulinaemia Patients.

Journal: Journal of clinical immunology

Published: April 15, 2024

Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

Journal: The Journal of allergy and clinical immunology

Published: April 08, 2023

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.

Journal: Blood

Published: October 27, 2022

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.

Journal: Allergy

Published: September 10, 2022

A National Survey of Hereditary Angioedema and Acquired C1 Inhibitor Deficiency in the United Kingdom.

A National Survey of Hereditary Angioedema and Acquired C1 Inhibitor Deficiency in the United Kingdom.

Journal: The journal of allergy and clinical immunology. In practice

Published: July 31, 2022

Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition.

Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition.

Journal: The lancet. Gastroenterology & hepatology

Published: July 19, 2022

Correction to: Inborn Errors of Immunity on the Island of Ireland - a Cross‑Jurisdictional UKPID/ESID Registry Report.

Correction to: Inborn Errors of Immunity on the Island of Ireland - a Cross‑Jurisdictional UKPID/ESID Registry Report.

Journal: Journal of clinical immunology

Published: June 22, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026